Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of karenitecin versus
topotecan in patients with platinum/taxane-resistant advanced epithelial ovarian cancer.
Additionally, this study will assess the ability of karenitecin to extend the time to disease
progression, extend the overall survival time, and reduce the incidence and severity of
treatment related hematological toxicities in patients with advanced epithelial ovarian
cancer.